The estimated Net Worth of Laurie C Torres is at least $127 Milion dollars as of 13 April 2007. Laurie Torres owns over 10,935 units of PDL Biopharma Inc stock worth over $127,353,102 and over the last 20 years Laurie sold PDLI stock worth over $0.
Sign up
Laurie Torres PDLI stock SEC Form 4 insiders trading
Laurie has made over 13 trades of the PDL Biopharma Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Laurie exercised 10,935 units of PDLI stock worth $145,326 on 13 April 2007.
The largest trade Laurie's ever made was exercising 39,375 units of PDL Biopharma Inc stock on 20 June 2005 worth over $523,294. On average, Laurie trades about 5,018 units every 39 days since 2004. As of 13 April 2007 Laurie still owns at least 35,317 units of PDL Biopharma Inc stock.
You can see the complete history of Laurie Torres stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Laurie Torres's mailing address?
Laurie's mailing address filed with the SEC is C/O PROTEIN DESIGN LABS, INC., 34801 CAMPUS DRIVE, FREMONT, CA, 94555.
Insiders trading at PDL Biopharma Inc
Over the last 22 years, insiders at PDL Biopharma Inc have traded over $45,966,964 worth of PDL Biopharma Inc stock and bought 12,693,393 units worth $32,804,545 . The most active insiders traders include Point Capital L.P.O'shea Ro..., Faheem Hasnain a Laurence Jay Korn. On average, PDL Biopharma Inc executives and independent directors trade stock every 24 days with the average trade being worth of $245,074,578. The most recent stock trade was executed by Point Capital L.P.O'shea Ro... on 1 February 2021, trading 187,061 units of PDLI stock currently worth $383,475.
What does PDL Biopharma Inc's logo look like?
Complete history of Laurie Torres stock trades at PDL Biopharma Inc
PDL Biopharma Inc executives and stock owners
PDL Biopharma Inc executives and other stock owners filed with the SEC include:
-
Dominique Monnet,
President, Chief Executive Officer, Director -
Christopher Stone,
Vice President, General Counsel, Secretary -
Edward Imbrogno,
Chief Financial Officer, Chief Accounting Officer, Vice President - Finance -
John McLaughlin,
Director -
David Gryska,
Independent Director -
Elizabeth O'Farrell,
Chairperson of the Board -
Natasha Hernday,
Independent Director -
Alan Bazaar,
Independent Director -
Danny J Jr. Hart,
Assoc Genl Counsel/Asst Sec -
Samuel R Saks,
Director -
Jody S Lindell,
Director -
Paul R Edick,
Director -
Harold E Selick,
Director -
Paul W Sandman,
Director -
Peter S Garcia,
Vice President, CFO -
Steffen Pietzke,
Controller and CAO -
Shlomo Yanai,
Director -
Jill M. Jene,
VP, Business Development -
Christine R Larson,
VP & Chief Financial Officer -
Joseph Iii Klein,
Director -
Karen J Wilson,
VP of Finance & PAO -
Mark Anthony Mc Camish,
SVP & CMO -
Brett L Schmidli,
SVP, Technical Operations -
Gary A Lyons,
Director -
Andrew Guggenhime,
SVP & Chief Financial Officer -
Faheem Hasnain,
President & CEO -
Francis Willard Sarena,
Exec Dir/Chief Legal Off/Secy -
Herb Cross,
Corp Controller/Prin Acctg Off -
Richard /Ca/ Murray,
Sr. VP & CSO -
Steven E Benner,
SVP and Chief Medical Officer -
Bradford S Goodwin,
Director -
Laurence Jay Korn,
Chairman of the Board -
Karen A Dawes,
Director -
Jaisim Shah,
Vice President, Marketing -
Jon S Saxe,
Director -
L Patrick Gage,
Director -
Glen Y Sato,
SVP and CFO -
Cynthia Lynn Shumate,
VP Legal Affrs, Secy & CCO -
Cary L Queen,
Senior Vice President -
Peter H Calcott,
VP, Quality & Compliance -
Laurie C Torres,
VP, Human Resources -
David Iwanicki,
VP, Sales & Sales Operations -
Mark Mcdade,
Chief Executive Officer -
Robert Michael Ii Savel,
SVP Technical Operations -
Samuel Broder,
Director -
George Jue,
VP, Fin & Corp. Controller -
Max Link,
Director -
Sergio Garcia Rodriguez,
VP, Legal and General Counsel -
Lyn D Olson,
VP, Quality and Compliance -
Douglas O Ebersole,
SVP, Legal & Corp Development -
George M Gould,
Director -
Jurgen Drews,
Director -
Behrooz Najafi,
V.P. IS and Corporate Services -
Corine Klingbell,
VP, Preclinical Development -
William R Benjamin,
VP, Research & Clinical Tech -
Frances G Charlson,
VP, Human Resources -
Patrick M Caldwell,
VP, Finance and Controller -
Mark P Backer,
VP, Technical Development -
David Montez,
Controller and CAO -
Fred Frank,
Director -
Bruce Tomlinson,
Chief Financial Officer -
Caroline J Krumel,
Vice President of Finance -
Point Capital L.P.O'shea Ro...,